



SUBFUND OVERVIEW

The fund's objective is to generate long-term capital appreciation by investing in a global portfolio composed principally of convertible bonds without any geographical or currency limitation. Convertible bonds are sensitive to movements in equities, credit, interest rates and volatility. Thus, according to the manager's macroeconomic assumptions, the portfolio parameters are set, with a bond or an equity bias. Thereafter, a selection process picks and weights around 50 to 60 investments to structure the portfolio. The fund is not benchmarked.

INVESTMENT MANAGER'S COMMENTS

This month, our top performance contributor has been **Depomed 2.5% 2021**. This specialty pharmaceutical company, focused on products to treat pain and other central nervous system (CNS) conditions, rose after Reuters reported that the company is readying a sale after it obtained a favourable ruling regarding its patent on NUCYNTA franchise its top drug. Around one year ago Horizon Pharma tried to buy Depomed for \$30 per share. At around \$25 we estimate that the stock has still a nice run to achieve before being fully valued.

Marine Harvest 0.875% 2019 came in second position. We have held this company for many years and reduced our holding several times after stellar performance in order to manage our delta risk. But we keep a nice allocation to this seafood company which is the largest producer of Atlantic Salmon in the world.

On the negative contribution side, we had **Post Holding 2.5% 2049** that gave back some of its very nice YTD performance (over 25%). **Teva 0.25% 2026** and **Allergan 5.5% 2018** continue to suffer from media and political focus, in this election year, regarding the high price of drugs in the Pharma sector. With that in mind, Teva should nevertheless benefit on the generic drug side of its business as

the worldwide leader and Allergan, being cash rich, through the M&A front. In conclusion, both companies are building a better future.

In terms of analysts reviews on our portfolio holdings, we would note: Berenberg made KPN, that we hold through the yield positive **America Movil /KPN 0% 2020**, its top pick for the remainder of 2016 considering that the market pressure on the stock is unfair and that it should be priced at or above the sector average and not a 15% discount. Barclays raised its price target on Micron giving a 25% expected return on the stock on improving pricing fundamentals. Jefferies lowered EPS expectation on Mediclinic but we keep the bond because of its low valuation and positive yield. At the same time, Jefferies maintained its buy rating on Sony with a 50% increase potential after Sony partnered with Wanda in China boosting Sony's prospects in the world's second largest movie market.

Finally, Berenberg held its annual German conference where a large number of convertible bond issuers gave an update on their business and Q&A sessions. This has been an opportunity to review and refresh our views on actual and potential investments.

NAV PER SHARE SINCE INCEPTION (CLASS A)



PERFORMANCE

	A	C	H
HEDGED	NO	CURRENCIES	CURRENCIES & DELTA
DELTA	49%	49%	8%
VOLATILITY	9.79%	7.42%	4.89%
NAV/SHARE	134.70	108.48	106.26
MONTH	-0.16%	0.25%	-0.29%
2016	-1.90%	-0.29%	-4.31%
2015	4.69%	-1.58%	0.95%
2014	14.17%	5.59%	9.85%
2013	3.88%	7.63%	0.15% *
2012	4.66%	1.40%	
2011	-12.34%	-7.26%	

* Since 01/07/2013

MAIN HOLDINGS

TOP 10	CCY	MATURITY / DURATION	PUT	%	DELTA	YTM/YTP	TOP 5 / BOTTOM 5 (ATTRIBUTION)
TAKE-TWO INTERACTIVE 1% 2018	USD	01/07/2018		3.67%	94%	0.00%	DEPOMED INC 2.5% 2021 0.25%
POST HOLDING 2.5% 2049	USD			3.14%	96%	1.67%	MARINE HARVEST 0.875% 2019 0.18%
ALLERGAN PLC 5.5% 2018	USD	01/03/2018		2.86%	72%	6.79%	PALO ALTO NETWORKS 0% 2019 0.08%
BANK OF AMERICA CORP 7.25% 2049	USD			2.14%	23%	5.94%	DRILLISCH AG 0.75% 2018 0.07%
TEVA PHARMA C 0.25% 2026	USD	01/02/2026	01/02/2016	2.10%	93%	0.00%	PRICELINE GROUP 1% 2018 0.06%
PARPUBLICA / GALP 5.25% 2017	EUR	28/09/2017	28/09/2015	2.07%	29%	0.00%	POST HOLDING 2.5% 2049 -0.31%
DRILLISCH AG 0.75% 2018	EUR	12/12/2018		2.03%	96%	0.00%	TEVA PHARMA C 0.25% 2026 -0.14%
PREMIER OIL 2.5% 2018	USD	27/07/2018		1.98%	7%	17.52%	ALLERGAN PLC 5.5% 2018 -0.06%
ORPEA 1.75% 2020	EUR	01/01/2020		1.98%	100%	0.00%	SIEMENS FINANCIERINGSMAT 1.05% 2017 -0.06%
AMERICA MOVIL SAB DE CV 0% 2020	EUR	28/05/2020		1.93%	21%	0.44%	STEINHOFF FINANCE HLDG 4% 2021 -0.06%
PORTFOLIO		4.38		100%	49%	2.53%	




BELLATRIX

ASSET MANAGEMENT


HARVEST INVESTMENT FUND Global Convertible UCITS IV

SEPTEMBER 2016


GEOGRAPHIC ALLOCATION




CURRENCY ALLOCATION



SECTOR ALLOCATION



CREDIT SPREAD



Source: Deutsche Bank

GENERAL INFORMATION

SHARE CLASS	ISIN	LAUNCH DATE	MAN. FEE	PERF. FEE	MIN. INVEST.	CLASS SHARES	SUBFUND ASSETS	CUT-OFF
A	LU0442197868	03/08/2009	1.85%	15% ABOVE 3-MONTHS LIBOR EUR (HIGH WATER MARK)	€ 1.000	CAPITALISATION	EUR 51 MILLIONS	DAILY 12:00 AM
B (INSTITUTIONAL)	LU0518233621	12/07/2010	1.20%		€ 1.000.000			
C (CURRENCY HEDGE)	LU0662027985	16/08/2011	1.85%		€ 1.000			
H (DELTA & CCY HEDGE)	LU0944844058	01/07/2013	1.85%		€ 1.000			

CUSTODIAN	VP Bank (Luxembourg) SA	INVESTMENT MANAGER	Bellatrix Asset Management S.A.
SUBSCRIPTIONS / REDEMPTIONS	VP Fund Solution (Luxembourg) SA		31, bd Prince Henri L-1724 Luxembourg
CENTRAL ADMIN / TA	FAX +352 404 770 283 TEL +352 404 770 260 luxfunds@vpbank.com		(+352) 26 25 66 20 info@bellatrix.lu
FUND	HARVEST INVESTMENT FUND 26, Av. de la Liberté L-1930 Luxembourg	ADVISOR	Harvest Advisory S.A.
		AUDITOR	Deloitte Audit S.à.r.l
		LEGAL ADVISOR	Elvinger, Hoss & Prussen

Investment Manager's comments are expressed by Bellatrix Asset Management S.A.. Periodic reports, the prospectus of the Fund, and the simplified prospectus of the subfund are available on request from Bellatrix Asset Management S.A. or at the registered office of the Fund. The present information note should not be considered as an offer to buy or sell shares. In order to constitute an offer, this document should be accompanied by the prospectus of the Fund, the simplified prospectus of the subfund and the latest periodic report. Although they are based on the best possible sources, the figures in this document have not been audited. Past performance is no guarantee of future performance as the net asset value of the portfolio of the subfund depends on market developments. Returns are net of management and performance fees.